Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s Prasugrel Hits Primary Goal in Japan PIII for Thrombotic Stroke, Filing for Label Expansion Planned in 2021
July 22, 2020
- MSD Launches Injectable Version of Deep Mycosis Drug Noxafil
July 22, 2020
- Japan Approves MSD’s 9-Valent HPV Vaccine 5 Years after Filing
July 21, 2020
- AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
- National CV Center Spin-Off Developing Oligonucleotide Therapy for Dyslipidemia, Eyes 1st Trial in FY2022
July 20, 2020
- Mitsubishi Tanabe Earns Indonesian OK for ALS Med
July 17, 2020
- Kyowa Pharma Expanding Focus Beyond Drugs, Eyes New Diagnostic/Treatment Options in CNS
July 17, 2020
- With New Chief at Helm, Mitsubishi Tanabe Looks to Boost Presence in Overseas Markets
July 16, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- SanBio to Focus on Cell Therapy SB623 for Brain Injury, Stroke, Seeking Licensees for Other Indications
July 16, 2020
- Astellas to Transfer Antipsychotic Dogmatyl to Nichi-Iko
July 15, 2020
- Eisai Starts PIII Preclinical Alzheimer’s Study for BAN2401
July 15, 2020
- Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
July 14, 2020
- Nichi-Iko Execs Face Pay Cuts over Massive Recalls
July 14, 2020
- Keio Prof. Kenya Honda Becomes Scientific Advisor for 4BIO
July 14, 2020
- Tecentriq Fails to Improve PFS in Ovarian Cancer: Roche/Chugai
July 14, 2020
- Treakisym Filed for Triple Therapy in DLBCL
July 14, 2020
- 23 Drug Makers to Invest US$1 Billion in “AMR Action Fund” to Develop 2-4 New Antibiotics by 2030
July 14, 2020
- Takeda Looks to Derive 70%-Plus of Japan Sales from 5 Focus Areas by FY2025, Revamp HR Systems
July 13, 2020
- Eisai Joins Forces with Four Universities on R&D of Lupus Drug
July 13, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…